{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:58Z","timestamp":1791478318979,"version":"4.3.4"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients with hyperlipidemia treated with statins remain at a residual cardiovascular (CV) risk. Omega-3 polyunsaturated fatty acids hold the potential to mitigate the residual CV risk in statin-treated patients, with persistently elevated triglyceride (TG) levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We reviewed the current evidence on the use of icosapent ethyl (IPE), an omega-3 fatty acid yielding a pure form of eicosapentaenoic acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>REDUCE-IT reported a significant 25% reduction in CV events, including the need for coronary revascularization, the risk of fatal\/nonfatal myocardial infarction, stroke, hospitalization for unstable angina, and CV death in patients on IPE, unseen with other omega-3 fatty acids treatments. IPE was effective in all patients regardless of baseline CV risk enhancers (TG levels, type-2 diabetes status, weight status, prior revascularization, or renal function). Adverse events (atrial fibrillation\/flutter) related to IPE have occurred mostly in patients with prior atrial fibrillation. Yet, the net clinical benefit largely exceeded potential risks. The combination with other omega-3 polyunsaturated fatty acids, in particular DHA, eliminated the effect of EPA alone, as reported in the STRENGTH and OMEMI trials. Adding IPE to statin treatment seems to be cost-effective, especially in the context of secondary prevention of CVD, decreasing CV event frequency and subsequently the use of healthcare resources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Importantly, IPE has been endorsed by 20 international medical societies as a statin add-on treatment in patients with dyslipidemia and high CV risk. Robust medical evidence supports IPE as a pillar in the management of dyslipidemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10557-023-07519-z","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T04:03:25Z","timestamp":1708056205000},"page":"1135-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6960-1056","authenticated-orcid":false,"given":"Hani","family":"Sabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Elhenawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Aljaberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layal","family":"Bennani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Fiad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khwaja","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Hashmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih A.","family":"Hijazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronney","family":"Shantouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"issue":"5","key":"7519_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2040622311413952","volume":"2","author":"MP Hermans","year":"2011","unstructured":"Hermans MP, Fruchart JC. Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. Ther Adv Chronic Dis. 2011;2(5):307\u201323.","journal-title":"Ther Adv Chronic Dis"},{"key":"7519_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","volume":"7","author":"DS Dhindsa","year":"2020","unstructured":"Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The evolving understanding and approach to residual cardiovascular risk management. Front Cardiovasc Med. 2020;7:88.","journal-title":"Front Cardiovasc Med"},{"issue":"Suppl 1","key":"7519_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11739-011-0669-5","volume":"6","author":"D Vanuzzo","year":"2011","unstructured":"Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011;6(Suppl 1):45\u201351.","journal-title":"Intern Emerg Med"},{"issue":"17","key":"7519_CR4","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374.","journal-title":"N Engl J Med"},{"issue":"22","key":"7519_CR5","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","volume":"361","author":"AJ Taylor","year":"2009","unstructured":"Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113\u201322.","journal-title":"N Engl J Med"},{"key":"7519_CR6","doi-asserted-by":"publisher","unstructured":"Burger AL, Pogran E, Muthspiel M, et al. New treatment targets and innovative lipid-lowering therapies in very-high-risk patients with cardiovascular disease. Biomedicines. 2022;10(5) https:\/\/doi.org\/10.3390\/biomedicines10050970.","DOI":"10.3390\/biomedicines10050970"},{"issue":"9677","key":"7519_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","volume":"373","author":"KK Ray","year":"2009","unstructured":"Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765\u201372.","journal-title":"Lancet"},{"issue":"1","key":"7519_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","volume":"116","author":"EL Schiffrin","year":"2007","unstructured":"Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85\u201397.","journal-title":"Circulation"},{"issue":"21","key":"7519_CR9","doi-asserted-by":"publisher","first-page":"e010596","DOI":"10.1161\/JAHA.118.010596","volume":"7","author":"Y Guo","year":"2018","unstructured":"Guo Y, Cui L, Ye P, et al. Change of kidney function is associated with all-cause mortality and cardiovascular diseases: results from the Kailuan study. J Am Heart Assoc. 2018;7(21):e010596.","journal-title":"J Am Heart Assoc"},{"key":"7519_CR10","doi-asserted-by":"crossref","unstructured":"The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. Jama. 1984;251(3):365\u201374.","DOI":"10.1001\/jama.1984.03340270043026"},{"issue":"1","key":"7519_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12944-019-1171-8","volume":"19","author":"YS Yao","year":"2020","unstructured":"Yao YS, Li TD, Zeng ZH. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis. 2020;19(1):23.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"7519_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195\u2013211.","journal-title":"Prim Care"},{"key":"7519_CR13","doi-asserted-by":"crossref","unstructured":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349\u201357.","DOI":"10.1056\/NEJM199811053391902"},{"issue":"9a","key":"7519_CR14","doi-asserted-by":"publisher","first-page":"3q","DOI":"10.1016\/S0002-9149(98)00769-3","volume":"82","author":"CM Ballantyne","year":"1998","unstructured":"Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol. 1998;82(9a):3q\u201312q.","journal-title":"Am J Cardiol"},{"issue":"suppl_F","key":"7519_CR15","doi-asserted-by":"publisher","first-page":"F34","DOI":"10.1093\/eurheartj\/sui041","volume":"7","author":"BG Brown","year":"2005","unstructured":"Brown BG. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J Suppl. 2005;7(suppl_F):F34\u201340.","journal-title":"Eur Heart J Suppl"},{"issue":"20","key":"7519_CR16","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. Jama. 1998;279(20):1615\u201322.","journal-title":"Jama"},{"issue":"2","key":"7519_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227\u201339.","journal-title":"Circulation"},{"key":"7519_CR18","doi-asserted-by":"crossref","unstructured":"Navar AM, Pagidipati N, Mulder H, et al. (2019) Triglycerides as a risk factor for coronary heart disease: what measure and what cutoff. in 68th Annual Scientific Session of the American College of Cardiology. New Orleans, LA","DOI":"10.1016\/S0735-1097(19)32471-4"},{"issue":"21","key":"7519_CR19","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Eng J Med. 2008;359(21):2195\u2013207.","journal-title":"New Eng J Med"},{"issue":"14","key":"7519_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001\u20139.","journal-title":"N Engl J Med"},{"issue":"8934","key":"7519_CR21","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study, G","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study, G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383\u20139.","journal-title":"Lancet"},{"issue":"20","key":"7519_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. New Eng J Med. 1995;333(20):1301\u20138.","journal-title":"New Eng J Med"},{"issue":"7","key":"7519_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724\u201330.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"7519_CR24","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","volume":"65","author":"GG Schwartz","year":"2015","unstructured":"Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65(21):2267\u201375.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"7519_CR25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","volume":"46","author":"P Libby","year":"2005","unstructured":"Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"7519_CR26","doi-asserted-by":"publisher","unstructured":"Graham I, Cooney MT. Risks in estimating risk. Eur Heart J. 2013:35. https:\/\/doi.org\/10.1093\/eurheartj\/eht286.","DOI":"10.1093\/eurheartj\/eht286"},{"issue":"13","key":"7519_CR27","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635\u2013701.","journal-title":"Eur Heart J"},{"issue":"1","key":"7519_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"7","key":"7519_CR29","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1097\/HJH.0b013e328136bd21","volume":"25","author":"DF Blackburn","year":"2007","unstructured":"Blackburn DF, Lamb DA, Eurich DT, et al. Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. J Hypertens. 2007;25(7):1499\u2013505.","journal-title":"J Hypertens"},{"issue":"12","key":"7519_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacc.2010.02.068","volume":"56","author":"MJ Jardine","year":"2010","unstructured":"Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol. 2010;56(12):956\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7519_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1681\/ASN.V122218","volume":"12","author":"LM Ruilope","year":"2001","unstructured":"Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12(2):218\u201325.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"7519_CR32","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1097\/00004872-200211000-00031","volume":"20","author":"A Zanchetti","year":"2002","unstructured":"Zanchetti A, Hansson L, Dahl\u00f6f B, et al. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. J Hypertens. 2002;20(11):2301\u20137.","journal-title":"J Hypertens"},{"issue":"12","key":"7519_CR33","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","volume":"165","author":"F Turnbull","year":"2005","unstructured":"Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410\u20139.","journal-title":"Arch Intern Med"},{"issue":"9374","key":"7519_CR34","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005\u201316.","journal-title":"Lancet"},{"issue":"9435","key":"7519_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685\u201396.","journal-title":"Lancet"},{"issue":"6","key":"7519_CR36","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2337\/dc05-2465","volume":"29","author":"J Shepherd","year":"2006","unstructured":"Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29(6):1220\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"7519_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-020-01037-0","volume":"19","author":"E Na","year":"2020","unstructured":"Na E, Cho S, Kim DJ, Choi J, Han E. Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study. Cardiovascular Diabetology. 2020;19(1):67.","journal-title":"Cardiovascular Diabetology"},{"issue":"24","key":"7519_CR38","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am College Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am College Cardiol"},{"issue":"27","key":"7519_CR39","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","volume":"39","author":"F Mach","year":"2018","unstructured":"Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526\u201339.","journal-title":"Eur Heart J"},{"issue":"13","key":"7519_CR40","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJMoa064278","volume":"357","author":"P Barter","year":"2007","unstructured":"Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301\u201310.","journal-title":"N Engl J Med"},{"issue":"15","key":"7519_CR41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"13","key":"7519_CR42","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jacc.2020.08.004","volume":"76","author":"MD Shapiro","year":"2020","unstructured":"Shapiro MD, Bhatt DL. \"Cholesterol-Years\" for ASCVD Risk Prediction and Treatment. J Am Coll Cardiol. 2020;76(13):1517\u201320.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"7519_CR43","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","volume":"36","author":"P Libby","year":"2015","unstructured":"Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015;36(13):774\u20136.","journal-title":"Eur Heart J"},{"issue":"4","key":"7519_CR44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. Jama. 2019;321(4):364\u201373.","journal-title":"Jama"},{"issue":"3","key":"7519_CR45","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","volume":"72","author":"OP Ganda","year":"2018","unstructured":"Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet Need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330\u201343.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"7519_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/CIRCULATIONAHA.104.504159","volume":"112","author":"M Cushman","year":"2005","unstructured":"Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112(1):25\u201331.","journal-title":"Circulation"},{"issue":"1","key":"7519_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u20138.","journal-title":"N Engl J Med"},{"issue":"20","key":"7519_CR48","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"PM Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557\u201365.","journal-title":"N Engl J Med"},{"issue":"1","key":"7519_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1161\/01.CIR.0000021112.29409.A2","volume":"106","author":"DL Bhatt","year":"2002","unstructured":"Bhatt DL, Topol EJ. Need to Test the Arterial Inflammation Hypothesis. Circulation. 2002;106(1):136\u201340.","journal-title":"Circulation"},{"issue":"1","key":"7519_CR50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.286.1.64","volume":"286","author":"MA Albert","year":"2001","unstructured":"Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study. Jama. 2001;286(1):64\u201370.","journal-title":"Jama"},{"key":"7519_CR51","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2217\/clp.11.54","volume":"6","author":"K Muhammad","year":"2011","unstructured":"Muhammad K, Morledge T, Sachar R, et al. Treatment with \u03c9-3 fatty acids reduces serum C-reactive protein concentration. Clinical Lipidology. 2011;6:723\u20139.","journal-title":"Clinical Lipidology"},{"issue":"1","key":"7519_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2018","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New Eng J Med. 2018;380(1):11\u201322.","journal-title":"New Eng J Med"},{"issue":"2","key":"7519_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","volume":"55","author":"RJ Glynn","year":"2009","unstructured":"Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem. 2009;55(2):305\u201312.","journal-title":"Clin Chem"},{"issue":"9567","key":"7519_CR54","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090\u20138.","journal-title":"Lancet"},{"issue":"6","key":"7519_CR55","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","volume":"70","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70(6):537\u201344.","journal-title":"J Cardiol"},{"issue":"4","key":"7519_CR56","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/cvr\/cvaa184","volume":"117","author":"MJ Budoff","year":"2020","unstructured":"Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovasc Res. 2020;117(4):1070\u20137.","journal-title":"Cardiovasc Res"},{"issue":"40","key":"7519_CR57","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","volume":"41","author":"MJ Budoff","year":"2020","unstructured":"Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925\u201332.","journal-title":"Eur Heart J"},{"issue":"3","key":"7519_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2337\/ds18-0009","volume":"31","author":"PS Jellinger","year":"2018","unstructured":"Jellinger PS. American Association of Clinical Endocrinologists\/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines. Diabetes Spectr. 2018;31(3):234\u201345.","journal-title":"Diabetes Spectr"},{"issue":"6","key":"7519_CR59","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/HCO.0000000000000678","volume":"34","author":"PN Patel","year":"2019","unstructured":"Patel PN, Patel SM, Bhatt DL. Cardiovascular risk reduction with icosapent ethyl. Curr Opin Cardiol. 2019;34(6):721\u20137.","journal-title":"Curr Opin Cardiol"},{"issue":"9500","key":"7519_CR60","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u201361.","journal-title":"Lancet"},{"key":"7519_CR61","doi-asserted-by":"crossref","unstructured":"Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New Eng J Med. 2010;362(17):1563\u201374.","DOI":"10.1056\/NEJMoa1001282"},{"key":"7519_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80\u201393.","journal-title":"Am Heart J"},{"issue":"21","key":"7519_CR63","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334.","journal-title":"N Engl J Med"},{"key":"7519_CR64","doi-asserted-by":"publisher","unstructured":"Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New Eng J Med. 2011. 365(24):2255-2267. https:\/\/doi.org\/10.1056\/NEJMoa1107579.","DOI":"10.1056\/NEJMoa1107579"},{"key":"7519_CR65","doi-asserted-by":"publisher","unstructured":"The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. New Eng J Med. 2014. 371(3):203-212. https:\/\/doi.org\/10.1056\/NEJMoa1300955.","DOI":"10.1056\/NEJMoa1300955"},{"key":"7519_CR66","doi-asserted-by":"crossref","unstructured":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999. 354(9177):447-55.","DOI":"10.1016\/S0140-6736(99)07072-5"},{"key":"7519_CR67","unstructured":"Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid (RESPECT-EPA). (UMIN Clinical Trials Registry Number: UMIN000012069). 2022; Available from: https:\/\/center6.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000014051."},{"issue":"1","key":"7519_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11883-019-0762-1","volume":"21","author":"R Preston Mason","year":"2019","unstructured":"Preston Mason R. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atherosclerosis Rep. 2019;21(1):2.","journal-title":"Curr Atherosclerosis Rep"},{"key":"7519_CR69","first-page":"100148","volume":"17","author":"PP Toth","year":"2022","unstructured":"Toth PP, Chapman MJ, Parhofer KG, Nelson JR. Differentiating EPA from EPA\/DHA in cardiovascular risk reduction. Am Heart J Plus: Cardiol Res Pract. 2022;17:100148.","journal-title":"Am Heart J Plus: Cardiol Res Pract"},{"key":"7519_CR70","unstructured":"Bavry AA and Bhatt DL. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy\u2013Statin and Eicosapentaenoic Acid - RESPECT-EPA. In American Heart Association Scientific Sessions. 2022. Chicago, IL."},{"issue":"3","key":"7519_CR71","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/clc.22692","volume":"40","author":"DL Bhatt","year":"2017","unstructured":"Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017;40(3):138\u201348.","journal-title":"Clin Cardiol"},{"issue":"4","key":"7519_CR72","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309\u201318.","journal-title":"N Engl J Med"},{"issue":"19","key":"7519_CR73","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","volume":"368","author":"MC Roncaglioni","year":"2013","unstructured":"Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800\u20138.","journal-title":"N Engl J Med"},{"issue":"21","key":"7519_CR74","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","volume":"122","author":"B Rauch","year":"2010","unstructured":"Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152\u20139.","journal-title":"Circulation"},{"issue":"16","key":"7519_CR75","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540\u201350.","journal-title":"N Engl J Med"},{"key":"7519_CR76","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cct.2015.12.022","volume":"47","author":"SS Bassuk","year":"2016","unstructured":"Bassuk SS, Manson JE, Lee IM, et al. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials. 2016;47:235\u201343.","journal-title":"Contemp Clin Trials"},{"issue":"8","key":"7519_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2021.1157","volume":"6","author":"SE Nissen","year":"2021","unstructured":"Nissen SE, Lincoff AM, Wolski K, et al. Association between achieved \u03c9-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH Trial. JAMA Cardiol. 2021;6(8):1\u20138.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"7519_CR78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","volume":"3","author":"T Aung","year":"2018","unstructured":"Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3(3):225\u201333.","journal-title":"JAMA Cardiol"},{"key":"7519_CR79","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383\u20139.","DOI":"10.1016\/S0140-6736(94)90566-5"},{"issue":"8","key":"7519_CR80","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","volume":"74","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am College Cardiol. 2019;74(8):1159\u201361.","journal-title":"J Am College Cardiol"},{"key":"7519_CR81","unstructured":"Bhatt DL, Brinton EA, Miller M, Steg G, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Ganda O, Welty FK, Busch RS, Goldberg AC, Herrington DM, Budoff M, Tardif JC, Ballantyne CM.\u00a0Icosapent Ethyl Provides Consistent Cardiovascular Benefit in Patients with Diabetes in REDUCE-IT.\u00a0On behalf of the REDUCE-IT investigators. https:\/\/www.acc.org\/education-and-meetings\/image-and-slide-gallery\/media-detail?id=EF9739685864453B84D5E26AC534A152"},{"key":"7519_CR82","doi-asserted-by":"publisher","unstructured":"Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Reduction in revascularization with icosapent ethyl: insights from REDUCE-IT revascularization analyses. Circulation. 2021;143(1):33\u201344. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050276.","DOI":"10.1161\/CIRCULATIONAHA.120.050276"},{"key":"7519_CR83","doi-asserted-by":"publisher","unstructured":"Peterson B, Bhatt D, Steg P, Miller M, Brinton E, Ketchum S, Juliano R, Jiao L, Doyle R, Granowitz C, Pinto D, Giugliano R, Budoff M, Tardif J\u2010C, Verma S, Ballantyne C.\u00a0Treatment with Icosapent Ethyl to Reduce Ischemic Events in Patients with Prior Percutaneous Cornoary Intervention: Insights From REDUCE-IT PCI. J Am Coll Cardiol. 2020;76(17):1\u20132. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.018.","DOI":"10.1016\/j.jacc.2020.09.018"},{"key":"7519_CR84","doi-asserted-by":"publisher","unstructured":"Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Icosapent ethyl reduces ischemic events in patients with a history of previous coronary artery bypass grafting: REDUCE-IT CABG. Circulation. 2021;144(23):1845\u20131855. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056290.","DOI":"10.1161\/CIRCULATIONAHA.121.056290"},{"key":"7519_CR85","unstructured":"Wang X, Bhatt DL, Miller M, Steg Ph.G, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz Jr. C, Copland C, Tardif J-C, Ballantyne CM, Budoff MJ, Mason RP, Boden WE, on Behalf of the REDUCE-IT Investigators, \u201cIcosapent Ethyl Reduces Ischemic Events in Patients with High Triglycerides and Low High-Density Lipoprotein Cholesterol Levels: REDUCE-IT High TG\/Low HDL-C Analyses\u201d, and it is available at: https:\/\/www.acc.org\/education-and-meetings\/image-and-slide-gallery\/media-detail?id=3f7acc9e9c254784924249b5e2fd4"},{"key":"7519_CR86","unstructured":"2021 ISC presentation (virtual), Bhatt DL, Steg Ph. G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz Jr. C, Tardif J-C, Gregson J, Gibson CM, Leary MC, Ballantyne CM, on Behalf of the REDUCE-IT Investigators, \u201cReductions in Ischemic Stroke with Icosapent Ethyl: Insights From REDUCE-IT\u201d, available online at ACC.org: https:\/\/www.acc.org\/education-and-meetings\/image-and-slide-gallery\/media-detail?id=c1fd107853f84abca5e552511ae756e7"},{"key":"7519_CR87","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Brinton EA, Miller M, Steg Ph. G, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz Jr. C, Tardif J-C, Ballantyne CM, on Behalf of the REDUCE-IT Investigators, ADA 2021 (virtual), \u201cSubstantial Cardiovascular Risk Reduction with Icosapent Ethyl Regardless of BMI or Diabetes Status: REDUCE-IT BMI\u201d. Restricted (login) access online at ADA: https:\/\/professional.diabetes.org\/webcast\/substantial-cardiovascular-risk-reduction-icosapent-ethyl-regardless-diabetes-status-or-bmie0d","DOI":"10.2337\/db21-256-OR"},{"key":"7519_CR88","doi-asserted-by":"publisher","unstructured":"Miller M, Bhatt DL, Steg PG, et al. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT Smoking. Eur Heart J Cardiovasc Pharmacother. 2022; https:\/\/doi.org\/10.1093\/ehjcvp\/pvac045.","DOI":"10.1093\/ehjcvp\/pvac045"},{"issue":"11","key":"7519_CR89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11892-020-01343-7","volume":"20","author":"X Wang","year":"2020","unstructured":"Wang X, Verma S, Mason RP, Bhatt DL. The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction. Curr Diab Rep. 2020;20(11):65.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"7519_CR90","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","volume":"40","author":"RP Mason","year":"2020","unstructured":"Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arteriosclerosis, Thrombosis Vas Biol. 2020;40(5):1135\u201347.","journal-title":"Arteriosclerosis, Thrombosis Vas Biol"},{"key":"7519_CR91","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.ajpc.2020.100130","volume":"4","author":"A Alfaddagh","year":"2020","unstructured":"Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130.","journal-title":"Am J Prev Cardiol"},{"issue":"22","key":"7519_CR92","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268\u201380.","journal-title":"JAMA"},{"issue":"6","key":"7519_CR93","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","volume":"143","author":"AA Kalstad","year":"2021","unstructured":"Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial. Circulation. 2021;143(6):528\u201339.","journal-title":"Circulation"},{"issue":"1","key":"7519_CR94","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMe1814004","volume":"380","author":"JJP Kastelein","year":"2019","unstructured":"Kastelein JJP, Stroes ESG. FISHing for the miracle of eicosapentaenoic acid. N Engl J Med. 2019;380(1):89\u201390.","journal-title":"N Engl J Med"},{"issue":"Supplement_J","key":"7519_CR95","doi-asserted-by":"publisher","first-page":"J34","DOI":"10.1093\/eurheartj\/suaa117","volume":"22","author":"B Olshansky","year":"2020","unstructured":"Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020;22(Supplement_J):J34\u201348.","journal-title":"Eur Heart J Suppl"},{"issue":"5","key":"7519_CR96","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"PM Ridker","year":"2022","unstructured":"Ridker PM, Rifai N, MacFadyen J, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1\u03b2, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation. 2022;146(5):372\u20139.","journal-title":"Circulation"},{"issue":"2","key":"7519_CR97","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jacc.2021.11.005","volume":"79","author":"N Singh","year":"2022","unstructured":"Singh N, Bhatt DL, Miller M, et al. Consistency of benefit of icosapent ethyl by background statin type in REDUCE-IT. J Am College Cardiol. 2022;79(2):220\u20132.","journal-title":"J Am College Cardiol"},{"issue":"Suppl_1","key":"7519_CR98","doi-asserted-by":"publisher","first-page":"A13685","DOI":"10.1161\/circ.146.suppl_1.13685","volume":"146","author":"SC Sherratt","year":"2022","unstructured":"Sherratt SC, Libby P, Bhatt DL, Mason P. Abstract 13685: Eicosapentaenoic Acid (EPA) Inhibits Low-Density Lipoprotein (LDL) Oxidation Compared to Docosahexaenoic Acid (DHA) and Mineral Oil in vitro. Circulation. 2022;146(Suppl_1):A13685.","journal-title":"Circulation"},{"key":"7519_CR99","doi-asserted-by":"crossref","unstructured":"Sherratt SCR, Libby P, Bhatt DL, Mason RP. Comparative effects of mineral oil, corn oil, eicosapentaenoic acid, and docosahexaenoic acid in an in vitro atherosclerosis model. J Am Heart Assoc. 2023;12(7):e029109.","DOI":"10.1161\/JAHA.122.029109"},{"issue":"4","key":"7519_CR100","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ehjci\/jet251","volume":"15","author":"R Puri","year":"2014","unstructured":"Puri R, Libby P, Nissen SE, et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014;15(4):380\u20138.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12 Suppl 4","key":"7519_CR101","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.3949\/ccjm.84.s4.01","volume":"84","author":"SE Nissen","year":"2017","unstructured":"Nissen SE, Nicholls SJ. Results of the GLAGOV trial. Cleve Clin J Med. 2017;84(12 Suppl 4):e1\u20135.","journal-title":"Cleve Clin J Med"},{"issue":"40","key":"7519_CR102","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1093\/eurheartj\/ehaa750","volume":"41","author":"L Tokgozoglu","year":"2020","unstructured":"Tokgozoglu L, Catapano AL. Can EPA evaporate plaques? Eur Heart J. 2020;41(40):3933\u20135.","journal-title":"Eur Heart J"},{"key":"7519_CR103","unstructured":"Bhatt D. EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl\u2013Intervention Trial. in ACC.20\/Wcc. 2020. Chicago."},{"issue":"7","key":"7519_CR104","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","volume":"52","author":"DO Kleindorfer","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2021;52(7):e364\u2013467.","journal-title":"Stroke"},{"issue":"9","key":"7519_CR105","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","volume":"78","author":"SS Virani","year":"2021","unstructured":"Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"7519_CR106","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"key":"7519_CR107","unstructured":"COUNCIL, S.N.D.C.S.a.t.S.H., Saudi Diabetes Clinical Practice Guidelines (SDCPG). 2021."},{"key":"7519_CR108","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S111\u2013S134. https:\/\/doi.org\/10.2337\/dc20-S010.","DOI":"10.2337\/dc20-S010"},{"issue":"19","key":"7519_CR109","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","volume":"141","author":"SV Arnold","year":"2020","unstructured":"Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020;141(19):e779\u2013806.","journal-title":"Circulation"},{"key":"7519_CR110","first-page":"1","volume":"2021","author":"DJ Gladstone","year":"2020","unstructured":"Gladstone DJ, Lindsay MP, Douketis J, et al. Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update. Can J Neurol Sci. 2020;2021:1\u201323.","journal-title":"Can J Neurol Sci"},{"key":"7519_CR111","doi-asserted-by":"publisher","unstructured":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019. 290: p. 140-205. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.014.","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"issue":"6","key":"7519_CR112","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","volume":"13","author":"CE Orringer","year":"2019","unstructured":"Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13(6):860\u201372.","journal-title":"J Clin Lipidol"},{"issue":"Supplement_J","key":"7519_CR113","doi-asserted-by":"publisher","first-page":"J21","DOI":"10.1093\/eurheartj\/suaa116","volume":"22","author":"KG Parhofer","year":"2020","unstructured":"Parhofer KG, Chapman MJ, Nordestgaard BG. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. Eur Heart J Suppl. 2020;22(Supplement_J):J21\u201333.","journal-title":"Eur Heart J Suppl"},{"key":"7519_CR114","doi-asserted-by":"publisher","unstructured":"Olshansky B, Bhatt D, Miller M, et al. Cardiovascular benefits outweigh risks in patients with atrial fibrillation in REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial). Eur Heart J. 2021;42(Supplement_1).\u00a0\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehab724.2568.","DOI":"10.1093\/eurheartj\/ehab724.2568"},{"issue":"5","key":"7519_CR115","doi-asserted-by":"publisher","first-page":"e026756","DOI":"10.1161\/JAHA.121.026756","volume":"12","author":"B Olshansky","year":"2023","unstructured":"Olshansky B, Bhatt DL, Miller M, et al. Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE IT. J Am Heart Assoc. 2023;12(5):e026756.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"7519_CR116","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. J Am College Cardiol. 2019;73(24):e285\u2013350.","journal-title":"J Am College Cardiol"},{"issue":"1","key":"7519_CR117","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/s41467-021-22370-2","volume":"12","author":"WS Harris","year":"2021","unstructured":"Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nature Commun. 2021;12(1):2329.","journal-title":"Nature Commun"},{"issue":"6","key":"7519_CR118","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41430-020-00751-y","volume":"75","author":"M Umesawa","year":"2021","unstructured":"Umesawa M, Yamagishi K, Iso H. Intake of fish and long-chain n-3 polyunsaturated fatty acids and risk of diseases in a Japanese population: a narrative review. Eur J Clin Nutr. 2021;75(6):902\u201320.","journal-title":"Eur J Clin Nutr"},{"issue":"19","key":"7519_CR119","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJM198505093121901","volume":"312","author":"D Kromhout","year":"1985","unstructured":"Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312(19):1205\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"7519_CR120","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1017\/S1368980011002254","volume":"15","author":"J Zheng","year":"2011","unstructured":"Zheng J, Huang T, Yu Y, et al. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutrition. 2011;15(4):725\u201337.","journal-title":"Public Health Nutrition"},{"issue":"3","key":"7519_CR121","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jamainternmed.2013.12765","volume":"174","author":"A Grey","year":"2014","unstructured":"Grey A, Bolland M. Clinical trial evidence and use of fish oil supplements. JAMA Intern Med. 2014;174(3):460\u20132.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"7519_CR122","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1475-9276-7-12","volume":"7","author":"MC Gemmill","year":"2008","unstructured":"Gemmill MC, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries. Int J Equity Health. 2008;7(1):12.","journal-title":"Int J Equity Health"},{"issue":"3","key":"7519_CR123","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/ehjqcco\/qcz001","volume":"5","author":"A Lamy","year":"2019","unstructured":"Lamy A, Lonn E, Tong W, et al. The cost implication of primary prevention in the HOPE 3 trial. Eur Heart J Qual Care Clin Outcomes. 2019;5(3):266\u201371.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"7519_CR124","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijcard.2016.06.126","volume":"220","author":"R Arbel","year":"2016","unstructured":"Arbel R, Hammerman A, Triki N, Greenberg D. PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them? Int J Cardiol. 2016;220:242\u20135.","journal-title":"Int J Cardiol"},{"issue":"12","key":"7519_CR125","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","volume":"2","author":"A Arrieta","year":"2017","unstructured":"Arrieta A, Hong JC, Khera R, et al. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER Trial. JAMA Cardiol. 2017;2(12):1369\u201374.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"7519_CR126","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.pcad.2019.10.004","volume":"62","author":"JG Robinson","year":"2019","unstructured":"Robinson JG. Lipid management beyond the guidelines. Prog Cardiovasc Dis. 2019;62(5):384\u20139.","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"7519_CR127","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11886-020-01356-4","volume":"22","author":"N Bazarbashi","year":"2020","unstructured":"Bazarbashi N, Miller M. Icosapent ethyl: niche drug or for the masses? Curr Cardiol Rep. 2020;22(10):104.","journal-title":"Curr Cardiol Rep"},{"issue":"11_Supplement_1","key":"7519_CR128","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0735-1097(20)32541-9","volume":"75","author":"WS Weintraub","year":"2020","unstructured":"Weintraub WS, Bhatt D, Zhang Z, et al. Cost-effectiveness of icosapent ethyl in us reduce-it patients. J Am College Cardiol. 2020;75(11_Supplement_1):1914.","journal-title":"J Am College Cardiol"},{"issue":"8","key":"7519_CR129","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1177\/2047487319896648","volume":"28","author":"Z Ademi","year":"2021","unstructured":"Ademi Z, Ofori-Asenso R, Zomer E, Owen A, Liew D. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. Eur J Prev Cardiol. 2021;28(8):897\u2013904.","journal-title":"Eur J Prev Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07519-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07519-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07519-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:14:17Z","timestamp":1762881257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07519-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7519"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07519-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"22 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Author Hani Sabbour is a speaker at Biologix events. All his honoraria were donated to patient-supporting charities in the UAE.Author Deepak Bhatt discloses the following relationships \u2013 Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures, Hims; Data Monitoring Committees: Acesion Pharma, Assistance Publique-H\u00f4pitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News,\n                      \n                      ; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi\/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today\u2019s Intervention), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women\u2019s Hospital who assigned to Lexicon; neither I nor Brigham and Women\u2019s Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald\u2019s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda.Author Layal Bennani is an employee of Biologix.Yaser Elhenawi, Asma Aljaberi, Tarek Fiad, Khwaja Hasan, Shahrukh Hashmani, Rabih A. Hijazi, Zafar Khan and Ronney Shantouf declare no conflicts of interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}